EPN 0.00% 2.4¢ epsilon healthcare limited

Ann: THC Global Southport Manufacturing Facility Licenced, page-43

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,039 Posts.
    lightbulb Created with Sketch. 572

    THC Global receives licence for Southern Hemisphere's largest cannabis bio-extraction facility

    Written on the 9 July 2019 by David Simmons

    THC Global receives licence for Southern Hemisphere's largest cannabis bio-extraction facility

    THC Global (ASX: THC) is poised for significant growth following the receipt of a licence allowing it to produce medicinal cannabis on an unprecedented scale.

    The listed medicinal cannabis company has received a manufacture licence for cannabis at its manufacturing facility at Southport on the Gold Coast, the largest bio-pharma extraction facility in the Southern Hemisphere.

    The licence will allow THC to begin producing cannabis which it intends to export around the world.

    THC estimates initial annual production from the Southport facility will be more than 12,000kg of medicinal cannabis.

    It is expected THC's target markets will continue to grow as more countries come on board with the legalisation of cannabis for medicinal purposes.

    THC Global also plans to produce proprietary finished medicines from the cannabis produced at this new facility, such as tinctures, oils and capsules.

    CEO Ken Charteris (pictured) says the receipt of the new licence is perhaps the most significant milestone in the company's history.

    "The Manufacture Licence we have now received is the most significant Manufacture Licence granted in Australia to date, as THC Global has the largest bio-pharma extraction facility in the Southern Hemisphere," says Charteris.

    "We are ready to commence GMP API (Good Manufacturing Practices compliant Active Pharmaceutical Ingredient) production of medicinal cannabis at globally significant volumes and at very competitive prices.

    "We expect to be supplying Australian patients with Australian produced medicinal cannabis by early 2020, as well as responding to the rapidly expanding global demand for pharma-grade GMP API isolates and formulated medicines."

    The company expects to become a leader in the APAC cannabis sector following the receipt of this licence, and one of the most competitive cannabis producers in the global export market.

    In addition to the Southport manufacturing facility, the company holds another licenced Manufacturing Facility in South East Queensland which also houses the company's proprietary cannabis strain development lab and cultivation facility.

    The company has secured an additional property in Northern NSW that it will develop into a large-scale organic cannabis cultivation facility of up to 150,000 square meters.

 
watchlist Created with Sketch. Add EPN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.